TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12473010
Drug: Facility characteristics
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facility characteristics (e.g., Medicare recipients, staffing levels, environmental quality)
Study: 12473010
Drug: Facility characteristics
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facility characteristics (e.g., for-profit ownership, chain affiliation)
Study: 2298963
Drug: Plasmapheresis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis therapy
Study: 2298963
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and immunosuppressive drugs alone (Control)
Study: 80682
Drug: Prednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (60 mg daily for one week, 40 mg daily for four days, and then 30 mg daily for three days)
Study: 27374276
Drug: Synthetic MK-7
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic MK-7 (180 µg)
Study: 27374276
Drug: Fermentation-derived MK-7
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermentation-derived MK-7 (90 µg)
Study: 27374276
Drug: Synthetic MK-7
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic MK-7 (45 µg)
Study: 27374276
Drug: Synthetic MK-7
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic MK-7 (90 µg)
Study: 25686683
Drug: 36 months
Normalized name: influenza virus vaccine qs 2016-17 (36 months up)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 months of isoniazid preventive therapy (36IPT)
Study: 25686683
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of isoniazid preventive therapy (6IPT)
Study: 24634622
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement splint (MAS) therapy
Study: 11391278
Drug: N-duopropenide alcohol
Normalized name: n-decyl alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-duopropenide alcohol solution (NDP)
Study: 9014908
Drug: Plasma Exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Exchange (PE) - five 50 mL/kg exchanges over 8-13 days
Study: 9014908
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Immunoglobulin (IVIg) - Sandoglobulin, 0.4 g/kg daily for 5 days
Study: 9014908
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (PE followed by IVIg)
Study: 9014908
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (PE + IVIg)
Study: 25494343
Drug: Post-treatment proposals
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment proposals participation
Study: 18669426
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of 2.5 mg of cyclosporine per kilogram of body weight
Study: 9485968
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml hyperbaric 0.5% bupivacaine
Study: 9485968
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml hyperbaric 0.5% bupivacaine
Study: 2422463
Drug: Nifedipine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (3 doses of 20 mg given sublingually at 8‐h intervals)
Study: 24627629
Drug: Exercise Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Therapy
Study: 23292820
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality (VR) supermarket (VMall) treatment, 10 sessions of 45 minutes each.
Study: 23292820
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (OT) cognitive retraining without VR, 10 sessions.
Study: 19139601
Drug: Strict treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict treatment to maintain systolic blood pressure below 140 mmHg
Study: 19139601
Drug: Mild treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild treatment to maintain systolic blood pressure below 160 but at or above 140 mmHg
Study: 10967067
Drug: L-NMMA (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (6 mg/kg over 5 minutes followed by 60 microg/kg per minute over 55 minutes)
Study: 10967067
Drug: L-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (3 mg/kg over 5 minutes followed by 30 microg/kg per minute over 55 minutes)
Study: 24569127
Drug: Alfacalcidol (ACD)
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (ACD) at 0.5 μg/day (n = 14)
Study: 7575103
Drug: Haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol at low plasma level (2 ng/mL)
Study: 7575103
Drug: Haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol at moderate plasma level (10 ng/mL)
Study: 2075079
Drug: Intravenous cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefuroxime 1,500 mg plus 500 mg metronidazole
Study: 7353344
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (15,000 U)
Study: 24084509
Drug: Almonds consumed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonds consumed with breakfast (43 g/day)
Study: 24084509
Drug: Almonds consumed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonds consumed as a morning snack (43 g/day)
Study: 24084509
Drug: Almonds consumed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonds consumed as an afternoon snack (43 g/day)
Study: 8996142
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC of 4 (AUC4) and cyclophosphamide 500 mg/m2
Study: 8996142
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC of 8 (AUC8) and cyclophosphamide 500 mg/m2
Study: 8512006
Drug: Metoprolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (up to 200 mg/die intravenously)
Study: 29522113
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) with dihydroartemisinin and piperaquine-phosphate, administered in 3 rounds over a 3-day course.
Study: 29522113
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) with dihydroartemisinin and piperaquine-phosphate.
Study: 26576633
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition group (treatment as usual)
Study: 18512165
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN) patches
Study: 18512165
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (stopping or continuing antihypertensive treatments)
Study: 15778907
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (lidocaine 5% patch, IBSA)
Study: 7577287
Drug: Clonidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (5 micrograms kg‐1) with famotidine 20 mg
Study: 7577287
Drug: Control (famotidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (famotidine 20 mg alone)
Study: 30967099
Drug: 1.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 mg/kg oral racemic MDA
Study: 25997508
Drug: Methyl aminolaevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl aminolaevulinate cream (MAL)
Study: 25997508
Drug: 5-ALA gel
Normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ALA gel (BF-200 ALA)
Study: 19567246
Drug: Francisella tularensis
Normalized name: Francisella tularensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(7) cfu/ml
Study: 19567246
Drug: Francisella tularensis
Normalized name: Francisella tularensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(9) cfu/ml
Study: 19567246
Drug: Francisella tularensis
Normalized name: Francisella tularensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(5) cfu/ml
Study: 19567246
Drug: Francisella tularensis
Normalized name: Francisella tularensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Francisella tularensis Live Vaccine Strain (LVS) via SQ at 10(5) cfu/ml
Study: 16397129
Drug: Tandem autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem autologous stem cell transplantation (ASCT) prepared by melphalan 220 mg/m(2) and 160 mg dexamethasone with or without anti-IL-6 monoclonal antibody (IFM99-04 protocol)
Study: 16397129
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell transplantation followed by dose-reduced allogeneic stem cell transplantation (IFM99-03 trial)
Study: 15132026
Drug: Walking whilst
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Walking whilst swinging arms at twice the natural frequency
Study: 9160765
Drug: Isradipine SRO
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine SRO (IS) 5 mg
Study: 9160765
Drug: Spirapril (SP)
DrugBank: Spirapril (DB01348)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spirapril (SP) 6 mg
Study: 2965232
Drug: ANP against
Normalized name: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s
DrugBank: Sutimlimab (DB14996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP against a nonpressor background infusion of ANG II
Study: 2965232
Drug: ANP against
Normalized name: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s
DrugBank: Sutimlimab (DB14996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP against a background infusion of ANG II
Study: 29799968
Drug: Daily sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sublingual buprenorphine with naloxone (SL-BPN/NX group)
Study: 29799968
Drug: Weekly and
Normalized name: Ezy Dose Weekly And Portable Pill Planner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly and monthly subcutaneous buprenorphine (SC-BPN group)
Study: 16337041
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day (n = 24)
Study: 10952950
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin and nimesulide
Study: 8793447
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 200, 400 or 800 micrograms b.i.d. as part of a self-management plan (SM)
Study: 8793447
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 200, 400 or 800 micrograms b.i.d. as part of a doctor-managed regimen (DM)
Study: 1661247
Drug: Psychologically oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychologically oriented treatment for alcoholism during hospitalization (16 +/- 10 days, 1 to 4 psychotherapeutic interviews)
Study: 1661247
Drug: Psychologically oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychologically oriented treatment for alcoholism
Study: 571202
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk with 1.75 g/kg of body weight of lactose
Study: 571202
Drug: Aqueous lactose
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous lactose solution
Study: 31470168
Drug: High-implant density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-implant density (HID)
Study: 31470168
Drug: Low-implant density
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-implant density (LID)
Study: 19133704
Drug: Armodafinil (50-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (50-400 mg, once daily for up to 14 days)
Study: 19133704
Drug: Armodafinil (50-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (50-400 mg)
Study: 16024131
Drug: IGF-I therapy
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-I therapy (20 microg/kg/day with dose escalation to 50-100 microg/kg/day for 4 months)
Study: 2792920
Drug: Oral tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tinidazole (150 mg X 2) for 7 days
Study: 2792920
Drug: Oral tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tinidazole (150 mg X 2) for 7 days with partner receiving 500 mg X 2 for 4 days
Study: 2792920
Drug: Intravaginal tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal tinidazole (500 mg) at bedtime for 2 weeks
Study: 2792920
Drug: Intravaginal tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal tinidazole (500 mg) at bedtime for 2 weeks with IUCD
Study: 2792920
Drug: Oral tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tinidazole (150 mg X 2) for 7 days with IUCD
Study: 2792920
Drug: Oral tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tinidazole (150 mg X 2) for 7 days with partner receiving 500 mg X 2 for 4 days and IUCD
Study: 18476432
Drug: Qianlie Huazhuo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianlie Huazhuo Capsule (QHC)
Study: 18476432
Drug: Qianlie Jiedu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianlie Jiedu Capsule (Control)
Study: 10540069
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion of propofol and remifentanil (125 microg of remifentanil added to 500 mg of propofol)
Study: 8712091
Drug: Bicalutamide (10-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (10-100 mg orally daily for 12 weeks)
Study: 7049311
Drug: Rectal metronidazole
Normalized name: metronidazole Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal metronidazole twice-daily for 5 days
Study: 7049311
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further antibacterial treatment
Study: 31445345
Drug: Escitalopram 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 30 mg per day
Study: 31445345
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg per day plus placebo
Study: 29911768
Drug: Single-shot sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot sciatic nerve block (SNB) with 0.25% bupivacaine 25 ml + continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Study: 29911768
Drug: Parenteral parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parenteral parecoxib 40 mg q 12 hours + continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Study: 29911768
Drug: Only continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Study: 25982007
Drug: Reinforcement-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement-Based Treatment (RBT) plus low cost Contingency Management (CM)
Study: 25982007
Drug: Reinforcement-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement-Based Treatment (RBT)
Study: 22464778
Drug: Warming kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming kidney prescription treatment
Study: 22464778
Drug: Control (telbivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (telbivudine monotherapy only)
Study: 8338943
Drug: Pentoxifylline (PTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (PTX), 1,600 mg/d in four divided doses from day -8 until day +100 post-BMT
Study: 3520988
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with azathioprine and high‐dose steroids
Study: 29284645
Drug: Parenting program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenting program focused on reading aloud; included borrowing children's books weekly and monthly parent workshops.
Study: 20012230
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell therapy
Study: 7498223
Drug: Planar thallium-201
Normalized name: thallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planar thallium-201 perfusion and FDG metabolism imaging
Study: 2108113
Drug: Aminoglycosides given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycosides given once daily (4.5 mg/kg bodyweight/day)
Study: 2108113
Drug: Aminoglycosides given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycosides given three times a day (4.5 mg/kg bodyweight/day)
Study: 2108113
Drug: Gentamicin once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin once daily
Study: 2108113
Drug: Nephrotoxicity across
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nephrotoxicity across all treatment groups
Study: 2108113
Drug: Aminoglycosides once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglycosides once daily
Study: 30716477
Drug: Genetically estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically estimated 25(OH)D concentration increase of 20 nmol/L for BE risk
Study: 30716477
Drug: Genetically estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically estimated 25(OH)D concentration increase of 20 nmol/L for EAC risk
Study: 29227571
Drug: Metformin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin IR
Study: 27741153
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment with Bifidobacterium breve BR03, B. breve B632, and Lactobacillus delbrueckii subsp. delbrueckii LDD01 at a concentration of 10 viable cells/strain/daily dose (5 drops)
Study: 25172877
Drug: Automated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated insulin pump system in adolescent subgroup
Study: 22965989
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus 81 mg of aspirin (n=28)
Study: 22965989
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg only (n=28)
Study: 20687826
Drug: Minocycline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline treatment for at least 2 weeks
Study: 1974071
Drug: Alpidem 25-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem 25-150 mg daily
Study: 1974071
Drug: Lorazepam 1-6
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1-6 mg daily
Study: 7262175
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prednisolone injection at three different doses
Study: 7262175
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone at five different doses
Study: 7262175
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and oral administration of prednisolone
Study: 31365188
Drug: Individual ROS
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual ROS tablets
Study: 26958466
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for chronic pain, 11-week duration
Study: 22797843
Drug: Enhanced communication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced communication therapy specific to aphasia or dysarthria, offered by speech and language therapists for up to four months.
Study: 22797843
Drug: Enhanced communication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced communication therapy
Study: 21302487
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen Dripping Pill (CDDP) 10 pills, thrice daily for 18 months
Study: 21302487
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen Dripping Pill (CDDP)
Study: 21302487
Drug: Aspirin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 0.1 g, once daily for 18 months
Study: 21302487
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 0.1 g, twice daily for 18 months
Study: 12059064
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with 0.1 mg/kg of midazolam
Study: 7605188
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol based bisacodyl suppositories (PGB)
Study: 7605188
Drug: Hydrogenated vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogenated vegetable oil based bisacodyl suppositories (HVB)
Study: 2371435
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms inhaled salbutamol